Does Aetna (CVS Health) Cover Metformin?
A clinical and coverage guide to Aetna (CVS Health) metformin coverage, prior authorization criteria, formulary tiers, step therapy requirements, and appeal pathways for type 2 diabetes and prediabetes.
76 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 60 of 76 clinical reviews.
A clinical and coverage guide to Aetna (CVS Health) metformin coverage, prior authorization criteria, formulary tiers, step therapy requirements, and appeal pathways for type 2 diabetes and prediabetes.
A complete guide to Blue Cross Blue Shield (Federated) coverage for metformin, including formulary tiers, prior authorization, step therapy, appeals, and out-of-pocket cost options.
Find out whether Humana covers metformin for type 2 diabetes and off-label uses, which formulary tier it sits on, prior-authorization rules, and how to appeal a denial.
A complete guide to Kaiser Permanente metformin coverage, formulary tier, prior authorization requirements, step therapy rules, and how to appeal a denial, with clinical context from UKPDS 34 and current ADA guidelines.
A complete guide to Medicare Advantage metformin coverage, formulary tiers, prior authorization, step therapy, and how to appeal a denial, with clinical context.
A state-by-state guide to Medicaid coverage of metformin for type 2 diabetes and prediabetes, including formulary tiers, prior authorization criteria, step therapy rules, and how to appeal a denial.
Metformin coverage under UnitedHealthcare is plan-specific. Learn how to verify the exact product, tier, pharmacy, and prior-authorization requirements without relying on stale coverage claims.
Stopping metformin cold turkey isn't advised: abrupt cessation can spike fasting glucose by 30 to 50 mg/dL. Taper by 500 mg every 1 to 2 weeks instead.
Metformin costs $4-$20/month generic; Januvia runs $450-$550 branded. Metformin also has stronger long-term outcomes data, per major guidelines.
Evidence-based guide to metformin dosing in adolescents aged 12 to 17 with type 2 diabetes, covering starting doses, titration timelines, extended-release options, GI management, and lab monitoring.
Evidence-based metformin dosing for adults aged 30 to 49, covering starting doses, titration schedules, maximum doses, renal thresholds, and real-world considerations for working-age patients with type 2 diabetes or prediabetes.
A clinical deep-dive into metformin use after bariatric surgery, covering pharmacokinetics, B12 depletion, RYGB vs sleeve gastrectomy differences, dosing, and when to stop or restart.
A clinical guide to metformin use in patients with autoimmune conditions, covering the immunomodulatory mechanisms under study, disease-specific considerations, drug interactions, and monitoring, with a clear line drawn between FDA-approved use and investigational use.
A clinician-level review of metformin's impact on cognitive function, covering mechanistic data, key trials, dosing considerations, and what current guidelines say about diabetes, aging, and brain health.
Metformin interacts with alcohol, high-fat meals, berberine, B12, magnesium, and calcium. See dosing context, trial data, and monitoring thresholds.
A clinician-level review of how metformin affects skeletal muscle, which patients face the greatest risk of lean-mass loss, and the evidence-based strategies to preserve muscle while staying on metformin therapy.
A citation-dense review of how metformin affects sexual function in men and women with type 2 diabetes, PCOS, and prediabetes. Covers testosterone, erectile dysfunction, libido, and clinical management strategies.
A clinician-level review of how metformin affects appetite, cravings, and food intake. Covers proposed mechanisms, clinical trial data, practical dosing context, and what patients can realistically expect.
A clinician-level review of how metformin affects bone mineral density, fracture risk, osteoblast activity, and osteoporosis outcomes in type 2 diabetes, with primary-literature citations throughout.
A clinician-level review of metformin's cancer risk signals, covering proposed mechanisms, key trials, confounding factors, and current guideline positions for patients with type 2 diabetes or prediabetes.
A clinician-level review of metformin's long-term cardiovascular effects, from UKPDS 34 through modern meta-analyses. Covers mechanisms, trial data, guideline positions, and practical prescribing context.
A comparison of compounded and branded metformin, covering bioequivalence, cost, formulation differences, safety, and how to choose the right option for type 2 diabetes or prediabetes management.
Metformin contraindications include poor kidney or liver function and heavy alcohol use. See who's at risk and what your labs mean before dosing.
Standard metformin dosing starts at 500mg with meals, up to 2,000mg daily max. Lowers HbA1c 1.0-1.5 points; backed by UKPDS 34 trial data.
How to dose metformin safely in adults aged 50 to 64, including starting doses, titration schedules, renal adjustments, and monitoring strategies based on clinical trial evidence.
Evidence-based metformin dosing guide for young adults aged 18 to 29, covering starting doses, titration schedules, fertility considerations, PCOS use, and ADA guidelines with primary source citations.
Metformin dosing by eGFR: full dose above 60, reduced dose 30-59 with monitoring, contraindicated below 30 mL/min/1.73 m2 per FDA label.
A physician-level breakdown of the metformin evidence base, with each major indication graded by GRADE certainty of evidence, key trial data, and practical clinical guidance.
A guide to using metformin for metabolic syndrome: what the trial data shows, how to dose it, who qualifies, and what side effects to watch for.
A guide to using metformin in NAFLD / MASLD patients: what the trials actually show, how to dose it, who benefits most, and where newer agents fit in.
A guide to metformin for prediabetes: what the DPP trial showed, who qualifies, how to dose, and what side effects to expect.
A deep dive into metformin's next-generation formulations, pipeline compounds, extended-release mechanisms, and emerging combination strategies backed by primary clinical evidence.
How to dose metformin safely in adults 65 and older. Covers renal-adjusted starting doses, titration schedules, eGFR thresholds, B12 monitoring, and deprescribing criteria backed by primary-source evidence.
Evidence-based monitoring guide for metformin in adults 65 and older. Covers renal function tracking, B12 screening, lactic acidosis risk, deprescribing criteria, and recommended lab intervals.
A guide to metformin's effects on hair loss, skin pigmentation, acne, and wound healing. Covers B12-mediated hair thinning, androgen-driven skin benefits in PCOS, and practical monitoring thresholds backed by primary literature.
A deep-dive into metformin's 100-year journey from plant alkaloid to the world's most-prescribed diabetes medication, covering its pharmacological roots, key clinical trials, and mechanism of action.
Metformin is avoided in severe liver disease (Child-Pugh C or AST/ALT over 3x ULN); mild-to-moderate cases may use cautious low-dose therapy.
Evidence-based review of metformin safety during pregnancy and breastfeeding, including MiG trial data, placental transfer, breast milk levels, and current ACOG/ADA guideline positions.
A clinician-level guide to metformin dosing, safety, and pharmacology in transplant recipients, people living with HIV, older adults, pregnant patients, and other special populations. Evidence-based, PubMed-cited.
Metformin is cleared renally, not by liver enzymes. Contrast dye, dolutegravir, topiramate, alcohol and cimetidine pose the biggest risks.
Metformin labs to monitor: eGFR at least yearly, B12 every 1-2 years after 4+ years on the drug, plus A1c targets and lactic acidosis risk for adults 50-64.
A deep dive into how metformin affects the liver, including NAFLD, lactic acidosis risk, hepatic glucose output, and safety in liver disease. Backed by primary-literature citations throughout.
A clinical deep-dive into metformin's manufacturing origins, global supply chain, FDA shortage events, NDMA recalls, and current availability for type 2 diabetes treatment.
A physician-level breakdown of how metformin works, from mitochondrial Complex I inhibition and AMPK activation to hepatic glucose suppression, gut signaling, and microbiome remodeling.
An evidence-based look at how metformin affects mental health and mood, covering depression, cognitive function, anxiety, B12 depletion, and clinical management guidance.
How metformin alters mitochondrial function, AMPK signaling, and hepatic glucose output, and what that means (and does not mean) for energy expenditure and weight. Written for clinicians and informed patients, pending qualified medical review.
A clinical review of metformin microdosing protocols for type 2 diabetes, prediabetes, longevity, and off-label use. Covers dosing thresholds, tolerability data, titration schedules, and what current guidelines do and do not support.
Missing one metformin dose usually causes only a modest fasting glucose rise of 15 to 30 mg/dL, not a crisis. Never double up; repeated gaps raise HbA1c.
Evidence-based metformin monitoring guide for adults aged 30 to 49. Covers baseline labs, follow-up intervals, renal function tracking, B12 screening, and red flags that signal a dose change.
Everything a young adult (18-29) needs to know about metformin monitoring: which labs to check, how often, warning signs, fertility considerations, and how to stay safe long-term.
A guide to metformin monitoring in adolescents aged 12 to 17, covering lab schedules, dose titration, growth considerations, mental-health screening, and safety signals.
Evidence-based metformin monitoring schedule covering HbA1c, renal function, B12, hepatic panels, and CBC. Includes timing, thresholds, and when to adjust or stop.
A clinician-grade review of metformin's off-label applications beyond type 2 diabetes, ranked by strength of evidence from randomized trials, meta-analyses, and guideline endorsements.
A guide to metformin overdose, accidental excess dosing, metformin-associated lactic acidosis (MALA), and evidence-based emergency management protocols.
A detailed history of metformin patents, generic approvals, extended-release formulations, and the current competitive field for the world's most prescribed diabetes drug.
Complete guide to monitoring children under 12 on metformin: dosing, labs, growth checks, GI side effects, and when to stop. Reviewed by HealthRX.com physicians.
A comprehensive, evidence-based review of metformin safety in children under 12, covering FDA labeling, dosing, monitoring, lactic acidosis risk, and clinical trial data reviewed by board-certified physicians.
A guide to metformin dosing in children under 12, covering FDA labeling, off-label evidence, weight-based protocols, titration schedules, and safety monitoring.
A clinician-level review of metformin pharmacogenomics, covering SLC22A1, SLC47A1, ATM, and other variants that explain why response to metformin differs so dramatically between patients.
A physician-level review of metformin pharmacokinetics covering oral bioavailability, transporter-mediated uptake via OCT1/OCT2, zero hepatic metabolism, and renal tubular secretion. Includes dosing implications for eGFR thresholds.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.

LegitScript certification
Verify HealthRX.comHealthRX.com is a platform connecting patients with independent licensed healthcare providers and pharmacies. Those providers deliver medical care and pharmacies dispense medication. Prescriptions are issued only when clinically appropriate. Payment does not guarantee a prescription.
Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Individual results vary.
Website information is educational and is not a substitute for personalized medical advice, diagnosis, or treatment. Consult your licensed healthcare provider.